Page last updated: 2024-09-03

gefitinib and camptothecin

gefitinib has been researched along with camptothecin in 66 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(camptothecin)
Trials
(camptothecin)
Recent Studies (post-2010) (camptothecin)
5,2315662,91913,0022,2295,391

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)camptothecin (IC50)
Histone deacetylase 3Homo sapiens (human)0.05
Multidrug resistance-associated protein 4Homo sapiens (human)7.4
DNA topoisomerase 1Homo sapiens (human)1.9799
Somatostatin receptor type 1Homo sapiens (human)0.0022
Somatostatin receptor type 2Homo sapiens (human)0.0022
Somatostatin receptor type 4Homo sapiens (human)0.0022
Somatostatin receptor type 3Homo sapiens (human)0.0022
Somatostatin receptor type 5Homo sapiens (human)0.0022
5-hydroxytryptamine receptor 2BHomo sapiens (human)0.97
Histone deacetylase 4Homo sapiens (human)0.05
Histone deacetylase 1Homo sapiens (human)0.05
Histone deacetylase 7Homo sapiens (human)0.05
Histone deacetylase 2Homo sapiens (human)0.05
Polyamine deacetylase HDAC10Homo sapiens (human)0.05
Histone deacetylase 11 Homo sapiens (human)0.05
Histone deacetylase 8Homo sapiens (human)0.05
Histone deacetylase 6Homo sapiens (human)0.05
Histone deacetylase 9Homo sapiens (human)0.05
Histone deacetylase 5Homo sapiens (human)0.05

Research

Studies (66)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's44 (66.67)29.6817
2010's20 (30.30)24.3611
2020's2 (3.03)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Kubota, K; Yoh, K1
Chu, E; Copur, S; DeGrendele, HC; Jain, VK; Lee, D; Maung, K; Schilsky, R1
Albanell, J; Baselga, J1
Fujiwara, K; Hamasaki, S; Kiura, K; Tabata, M; Tanimoto, M; Ueoka, H1
Kanzawa, F; Koh, Y; Koizumi, F; Nishio, K; Saijo, N; Taguchi, F; Tamura, T; Tsukiyama, S; Ueda, Y1
Asai Go, Go; Fukuoka, M; Kaneda, H; Kurata, T; Nakagawa, K; Nogami, T; Tamura, K; Uejima, H1
Hayakawa, Y1
Azzariti, A; Paradiso, A; Porcelli, L; Xu, JM1
Asada, S; Imai, Y; Ishikawa, E; Sugimoto, Y; Tsukahara, S; Yanase, K1
Cheshire, PJ; Daw, N; Germain, GS; Gilbertson, R; Harwood, FC; Houghton, PJ; Jenkins, JJ; Leggas, M; Panetta, JC; Peterson, J; Schuetz, JD; Stewart, CF1
Kishida, O; Kiyohara, T; Miyazaki, T; Miyazaki, Y; Murayama, Y; Ogasa, M; Shimomura, I; Shinomura, Y; Tsutsui, S; Watabe, K; Yamamoto, T2
Doi, S; Ikegami, Y; Itoh, A; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M1
Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML1
Masuda, N; Yanase, N; Yokoba, M1
Advani, RH; Cho, CD; Fisher, GA; Ford, JM; Halsey, J; Kuo, T; Sikic, BI; Wakelee, HA1
Ando, Y; Araki, K; Endo, H; Fujita, K; Kodama, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Yamamoto, W1
Brahmandam, M; Cantor, M; Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kinsella, K; Kulke, MH; Loda, M; Meyerhardt, JA; Michelini, AL; Namgyal, C; Ogino, S; Ryan, DP1
Braun, AH; Dirsch, O; Hilger, RA; Seeber, S; Stark, K; Vanhoefer, U1
Fukuda, M; Kitazaki, T; Kohno, S; Nagashima, S; Nakamura, Y; Oka, M; Shiozawa, K; Soda, H; Takemura, M; Tsukamoto, K; Yabuuchi, H1
Iwashige, A; Kagami, S; Tsukada, J; Uramoto, H1
Borner, MM1
Fukumoto, H; Kiura, K; Koizumi, F; Nishio, K; Saijo, N; Shimoyama, T; Tanimoto, M1
Sandler, AB1
Eng, C; Shalan, N1
Katakami, N1
Battu, S; Blaszkowsky, L; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Meyerhardt, JA; Ryan, DP; Wolpin, BM; Zhu, AX1
Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J1
Hanada, M; Noguchi, T; Yamaoka, T1
Clark, JW; D'Amato, F; Dancey, J; Earle, CC; Eder, JP; Enzinger, PC; Fuchs, CS; Kinsella, K; Mayer, RJ; Meyerhardt, JA; Michelini, A; Ogino, S; Ryan, DP; Stewart, CF; Supko, JG; Zhu, AX1
Azzariti, A; Han, Y; Li, YM; Li, ZQ; Paradiso, A; Wang, Y; Xu, JM; Yang, WW; Yuan, SJ; Zhao, CH1
Botwood, N; Chau, I; Cunningham, D; Hickish, T; Higgins, L; Massey, A; Osborne, R; Swaisland, A1
Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kulke, MH; Loda, M; Meyerhardt, JA; Ogino, S; Ryan, DP; Wolpin, BM1
Fujiwara, Y; Hisamoto, A; Hotta, K; Ichihara, E; Kiura, K; Kozuki, T; Ohashi, K; Osawa, M; Shibayama, T; Tabata, M; Tada, A; Takahashi, K; Takata, S; Takeyama, M; Takigawa, N; Tanimoto, M; Umemura, S1
Yoneda, S1
Bendell, JC; Clark, JW; Czito, BG; Duda, DG; Jain, RK; Willett, CG1
Noda, K; Oshita, F; Saito, H; Yamada, K1
Halle, JS; Hayes, DN; Lee, CB; Moore, DT; Morris, DE; Rivera, MP; Rosenman, JG; Socinski, MA; Stinchcombe, TE1
Bokemeyer, C; Hartmann, JT; Höhler, T; Holtmann, M; Kröning, H; Pintoffl, JP1
Carnaghi, C; Comandone, A; Granetti, C; Lorusso, V; Mari, E; Oliva, C; Pressiani, T; Rimassa, L; Ronzoni, M; Santoro, A; Siena, S; Zuradelli, M1
Ikegami, Y; Ito, A; Kohno, S; Nakamura, Y; Nakano, H; Oka, M; Sano, K; Satake, K; Sawada, S; Soda, H; Yoshida, H; Yoshikawa, M1
Azzariti, A; Berardi, F; Colabufo, NA; D'Incalci, M; Paradiso, A; Perrone, R; Porcelli, L; Quatrale, AE; Simone, GM; Xu, JM; Zucchetti, M1
Crews, KR; Daw, NC; Furman, WL; Gajjar, AJ; Houghton, PJ; McCarville, MB; McGregor, LM; Navid, F; Panetta, JC; Rodriguez-Galindo, C; Santana, VM; Spunt, SL; Stewart, CF; Wu, J1
Kondo, T; Murakami, S; Oshita, F; Saito, H; Yamada, K1
Teng, KY; Xu, RH1
Glynne-Jones, R; Harrison, M; Mawdsley, S1
Fujimoto, N; Fujiwara, Y; Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M; Toyooka, S; Ueoka, H; Umemura, S1
Billups, CA; Davidoff, AM; Furman, WL; Hawkins, D; Houghton, PJ; Kovach, S; McCarville, MB; McGregor, LM; McPherson, V; Onciu, M; Santana, VM; Stewart, CF; Wu, J1
Horai, T; Horiike, A; Kasahara, K; Kudo, K; Miyauchi, E; Nishio, M; Ohyanagi, F1
Hasegawa, T; Hirakawa, K; Matsuzaki, T; Qiu, H; Yashiro, M; Zhang, X1
Fujimura, M; Kasahara, K; Kimura, H; Nakao, S; Ohmori, T; Sakai, A; Sone, T1
Cassidy, J; Hochster, H1
Bobilev, D; Peleg, R; Priel, E1
Ikegami, Y; Inoue, Y; Ishikawa, T; Nakagawa, H; Nakamura, Y; Sano, K; Suzuki, T; Yoshida, H1
Yano, S1
Brennan, RC; Furman, W; Mao, S; McGregor, LM; Santana, V; Stewart, CF; Turner, DC; Wu, J1
Apte, RN; Kogan-Zviagin, I; Peleg, R; Priel, E; Romzova, M1
Li, W; Liu, Y; Xing, Y1
Chen, M; He, Q; Luo, P; Peng, X; Shao, J; Xu, L; Xu, Z; Yang, B; Zhu, H; Zhu, Y1
Nanbu, K; Nanbu, T; Ohkoshi, E; Sakagami, H; Shimada, J; Umemura, N1
Hemler, ME; Hwang, S; Takimoto, T1
Freeman, MR; Hemler, ME; Sharma, C; Steen, H; Yang, W1
Gong, P; Jiang, Y; Li, H; Wu, Y; Zhang, J; Zheng, P; Zhou, Y1

Reviews

12 review(s) available for gefitinib and camptothecin

ArticleYear
[New treatment strategy for stage III non-small-cell lung cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quinazolines; Radiotherapy; Taxoids; Treatment Outcome; Vinblastine

2002
Epithelial growth factor receptor interacting agents.
    Hematology/oncology clinics of North America, 2002, Volume: 16, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunization, Passive; Irinotecan; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms; Quinazolines; Recombinant Fusion Proteins; Xenograft Model Antitumor Assays

2002
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:6

    Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine

2005
[Chemotherapy for lung cancer patients].
    Journal of UOEH, 2006, Mar-01, Volume: 28, Issue:1

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Etoposide; Evidence-Based Medicine; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids

2006
[Molecular targets in colon cancer].
    Therapeutische Umschau. Revue therapeutique, 2006, Volume: 63, Issue:4

    Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolones; Receptors, Platelet-Derived Growth Factor; Receptors, Somatomedin; Signal Transduction; Sirolimus; Sunitinib

2006
Nondermatologic adverse events associated with anti-EGFR therapy.
    Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:5 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Irinotecan; Lung Diseases, Interstitial; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines

2006
Biological agents versus chemotherapy in the treatment of colorectal cancer.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Irinotecan; Phthalazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A

2006
Targeted therapy in rectal cancer.
    Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Irinotecan; Neoadjuvant Therapy; Quinazolines; Rectal Neoplasms; Vascular Endothelial Growth Factor A

2007
[Progress in chemotherapy for advanced gastric cancer].
    Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Fluorouracil; Gefitinib; Humans; Irinotecan; Methotrexate; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Quinazolines; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Trastuzumab

2009
Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
    Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:3

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Rectal Neoplasms; Treatment Failure

2010
New oxaliplatin-based combinations in the treatment of colorectal cancer.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2003, Volume: 5 Suppl 3

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Quinazolines; Thiophenes

2003
[Programs for continuing medical education: B session; 4. Progress in lung cancer therapy].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Mar-10, Volume: 103, Issue:3

    Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Crizotinib; Drug Discovery; Education, Medical, Continuing; Erlotinib Hydrochloride; Etoposide; Gefitinib; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Small Cell Lung Carcinoma

2014

Trials

16 trial(s) available for gefitinib and camptothecin

ArticleYear
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
    British journal of cancer, 2005, May-23, Volume: 92, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dehydration; Diarrhea; Drug Interactions; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Quinazolines; Treatment Outcome

2005
Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Treatment Outcome

2005
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-15, Volume: 11, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Cell Cycle Proteins; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; DNA Mutational Analysis; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Quinazolines; ras Proteins; Treatment Outcome; Tumor Suppressor Protein p53; Tumor Suppressor Proteins

2005
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.
    Clinical colorectal cancer, 2006, Volume: 6, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines

2006
Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
    Onkologie, 2006, Volume: 29, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Gastrointestinal Diseases; Gefitinib; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Risk Assessment; Treatment Outcome

2006
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Quinazolines

2007
Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Male; Middle Aged; Mutation; Quinazolines

2007
Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Organoplatinum Compounds; Quinazolines

2008
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small ce
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Contraindications; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2008
Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).
    Onkologie, 2008, Volume: 31, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Maximum Allowable Concentration; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Risk Assessment; Risk Factors; Treatment Outcome

2008
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Quinazolines

2008
Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-20, Volume: 27, Issue:27

    Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biological Availability; Camptothecin; Child; Child, Preschool; Drug Synergism; Female; Gefitinib; Humans; Infant; Infusions, Intravenous; Irinotecan; Male; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Toxicity Tests; Young Adult

2009
Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer.
    American journal of clinical oncology, 2010, Volume: 33, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Survival Rate; Treatment Outcome

2010
A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.
    Investigational new drugs, 2012, Volume: 30, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Female; Gefitinib; Homovanillic Acid; Humans; Immunohistochemistry; Infant; Infant, Newborn; Irinotecan; L-Lactate Dehydrogenase; Male; Neoplasm Proteins; Neuroblastoma; Pilot Projects; Quinazolines; Risk Factors; Treatment Outcome; Tumor Burden; Vanilmandelic Acid

2012
Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer.
    British journal of cancer, 2011, Oct-11, Volume: 105, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Quinazolines; Treatment Outcome

2011
Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:6

    Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Camptothecin; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Interactions; Female; Gefitinib; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; Quinazolines; Treatment Outcome; Young Adult

2014

Other Studies

38 other study(ies) available for gefitinib and camptothecin

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines

2002
Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status.
    Lung cancer (Amsterdam, Netherlands), 2003, Volume: 40, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Salvage Therapy; Taxoids; Treatment Outcome

2003
Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
    International journal of cancer, 2004, Jan-20, Volume: 108, Issue:3

    Topics: Animals; Apoptosis; Camptothecin; Cell Division; Colorectal Neoplasms; DNA Topoisomerases, Type I; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Poly(ADP-ribose) Polymerases; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2004
Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Retreatment; Taxoids

2004
[Structure-activity relationship analysis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Camptothecin; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Imatinib Mesylate; Irinotecan; Macrolides; Oligopeptides; Paclitaxel; Piperazines; Pyrimidines; Quinazolines; Structure-Activity Relationship; Taxoids; Topotecan; Vinblastine

2004
The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).
    Biochemical pharmacology, 2004, Jul-01, Volume: 68, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Division; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Synergism; ErbB Receptors; Gefitinib; HT29 Cells; Humans; Irinotecan; Quinazolines; Signal Transduction; Tumor Cells, Cultured

2004
Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:9

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrone; Gefitinib; Humans; Irinotecan; Neoplasm Proteins; Quinazolines; Topotecan

2004
Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
    Cancer research, 2004, Oct-15, Volume: 64, Issue:20

    Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Bone Neoplasms; Camptothecin; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Mice; Mice, Inbred ICR; Mice, SCID; Neoplasm Proteins; Osteosarcoma; Quinazolines; Xenograft Model Antitumor Assays

2004
Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
    Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:6

    Topics: Amphiregulin; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Screening Assays, Antitumor; EGF Family of Proteins; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glycoproteins; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Irinotecan; Phosphorylation; Quinazolines; Reactive Oxygen Species; Signal Transduction; Stomach Neoplasms; Transforming Growth Factor alpha; Tyrosine

2005
Gefitinib ("Iressa", ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
    Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:4

    Topics: Adenocarcinoma; Amphiregulin; Antineoplastic Agents; Camptothecin; EGF Family of Proteins; ErbB Receptors; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Irinotecan; Metalloproteases; Phosphorylation; Quinazolines; Reactive Oxygen Species; Stomach Neoplasms; Transforming Growth Factor alpha; Tumor Cells, Cultured

2005
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Cancer research, 2005, Feb-15, Volume: 65, Issue:4

    Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Topotecan

2005
Gefitinib (Iressa) inhibits the CYP3A4-mediated formation of 7-ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin but activates that of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin from irinotecan.
    Drug metabolism and disposition: the biological fate of chemicals, 2005, Volume: 33, Issue:12

    Topics: Camptothecin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Gefitinib; Humans; Irinotecan; Microsomes, Liver; Midazolam; Quinazolines

2005
The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.
    Anti-cancer drugs, 2005, Volume: 16, Issue:10

    Topics: Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Cyclin E; DNA Topoisomerases, Type II; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Irinotecan; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction

2005
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
    Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:5

    Topics: Adenosine Triphosphatases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Fluorescence; Topoisomerase I Inhibitors; Topotecan

2006
Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR.
    Lung cancer (Amsterdam, Netherlands), 2006, Volume: 53, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Mice; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Deletion; Survival Rate; Tumor Cells, Cultured

2006
[Lung cancer with bone metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:8

    Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids

2006
Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
    Cancer science, 2007, Volume: 98, Issue:3

    Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gefitinib; Gemcitabine; Humans; In Vitro Techniques; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Stomach Neoplasms; Tegafur; Trastuzumab; Uracil; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays

2007
[Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2006, Volume: 28, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Synergism; ErbB Receptors; Gefitinib; HT29 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction

2006
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
    Virchows Archiv : an international journal of pathology, 2007, Volume: 450, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; CpG Islands; DNA Methylation; Female; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Male; Massachusetts; Microsatellite Instability; Middle Aged; Quinazolines; Survival Rate

2007
Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
    Oncology reports, 2007, Volume: 17, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gefitinib; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Piperazines; Pyrimidines; Quinazolines

2007
[Outpatient chemotherapy for lung cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:4

    Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine

2007
Gefitinib increases serum concentrations of oral irinotecan and SN-38 without increasing the biliary concentration of SN-38 in rats.
    Chemotherapy, 2008, Volume: 54, Issue:6

    Topics: Administration, Oral; Animals; Biliary Tract; Camptothecin; Gefitinib; Irinotecan; Male; Quinazolines; Rats; Rats, Wistar

2008
Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:2

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Line; Cell Line, Tumor; Dogs; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gefitinib; Humans; Irinotecan; Mitoxantrone; Neoplasm Proteins; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Time Factors

2010
Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
    Acta medica Okayama, 2010, Volume: 64, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Signet Ring Cell; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids

2010
An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.
    British journal of cancer, 2011, Nov-08, Volume: 105, Issue:10

    Topics: Animals; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Irinotecan; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Stomach Neoplasms

2011
MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:9

    Topics: Antineoplastic Agents; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Lung Neoplasms; Proto-Oncogene Proteins c-met; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Topoisomerase I Inhibitors; Tumor Cells, Cultured

2012
Topoisomerase I as a target of erlotinib and gefitinib: efficacy of combined treatments with camptothecin.
    International journal of oncology, 2014, Volume: 44, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Erlotinib Hydrochloride; Female; Gefitinib; Humans; MCF-7 Cells; Molecular Targeted Therapy; Protein Processing, Post-Translational; Quinazolines

2014
Gefitinib enhances the antitumor activity of CPT-11 in vitro and in vivo by inhibiting ABCG2 but not ABCB1: a new clue to circumvent gastrointestinal toxicity risk.
    Chemotherapy, 2013, Volume: 59, Issue:4

    Topics: Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Cell Survival; Diarrhea; Drug Synergism; Drug Therapy, Combination; Female; Gefitinib; HEK293 Cells; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Quinazolines; RNA, Messenger; Transplantation, Heterologous

2013
Modification of topoisomerases in mammospheres derived from breast cancer cell line: clinical implications for combined treatments with tyrosine kinase inhibitors.
    BMC cancer, 2014, Dec-03, Volume: 14

    Topics: Animals; Antigens, Surface; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Topoisomerases; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Synergism; Enzyme Activation; Etoposide; Female; Gefitinib; Humans; Immunophenotyping; MCF-7 Cells; Mice; Neoplastic Stem Cells; Quinazolines; Spheroids, Cellular; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured

2014
Inhibition of SN-38 glucuronidation by gefitinib and its metabolite.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:6

    Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Drug Combinations; Drug Interactions; Gefitinib; Glucuronosyltransferase; Humans; Irinotecan; Microsomes, Liver; Quinazolines

2015
Gefitinib Synergizes with Irinotecan to Suppress Hepatocellular Carcinoma via Antagonizing Rad51-Mediated DNA-Repair.
    PloS one, 2016, Volume: 11, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Hep G2 Cells; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Rad51 Recombinase; RNA, Small Interfering; Topoisomerase I Inhibitors

2016
Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells.
    Oncology reports, 2018, Volume: 39, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gefitinib; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Irinotecan; Lysosomes; Mice; Proteolysis; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays

2018
Integrin-independent support of cancer drug resistance by tetraspanin CD151.
    Cellular and molecular life sciences : CMLS, 2019, Volume: 76, Issue:8

    Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Humans; Integrins; Laminin; Neoplasms; RNA, Messenger; Tetraspanin 24

2019
Antioxidant functions of DHHC3 suppress anti-cancer drug activities.
    Cellular and molecular life sciences : CMLS, 2021, Volume: 78, Issue:5

    Topics: Acyltransferases; Antineoplastic Agents; Antioxidants; Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Female; Gefitinib; Humans; Lapatinib; Male; Prostatic Neoplasms; RNA Interference

2021
Theoretical Study on the Aggregation and Adsorption Behaviors of Anticancer Drug Molecules on Graphene/Graphene Oxide Surface.
    Molecules (Basel, Switzerland), 2022, Oct-10, Volume: 27, Issue:19

    Topics: Adsorption; Anastrozole; Antineoplastic Agents; Camptothecin; Gefitinib; Graphite; Molecular Dynamics Simulation; Resveratrol

2022